Antibody-directed and drug therapies have been on the forefront of immuno-oncology research in the past 15 years. Since the FDA introduced the Breakthrough Therapy Designation in 2016 for novel promising drug therapies, the number of applicants and approved candidates has increased dramatically. As more and more researchers are looking at drug effects in cancer cells and moving forward in drug discovery, they face many challenges in their day to do work. Performing cell cytotoxicity assays for multiple cell lines with single and combination drug therapies is standard practice in immuno-oncology. While many researches use end-point assays such as MTT, XTT, WST, or CellTiter-Glo, others prefer the manual [...]